Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Bomba, M ^a,b   Ciavardelli, D ^a,c,d   Silvestri, E ^e   Canzoniero, L M T ^e   Lattanzio, R ^d   Chiappini, P ^d   Piantelli, M ^d   Di Ilio, C ^d   Consoli, A ^d   Sensi, S L ^a,b,f  

^a University Gd Annunzio Chieti Pescara   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c KORE UNIVERSITY OF ENNA   (Italy)

^d Gd Annunzio University   (Italy)

^e UNIVERSITY OF SANNIO   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3xTg AD mice; Alzheimer's disease; Brain metabolism; Exenatide; PS1 KI mice

Indexed keywords

EXENDIN 4; LACTATE DEHYDROGENASE; PRESENILIN 1;

ALZHEIMER DISEASE; ANAEROBIC GLYCOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; BRAIN MITOCHONDRION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; LONG TERM MEMORY; MALE; MENTAL PERFORMANCE; MITOCHONDRIAL RESPIRATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SHORT TERM MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; COGNITION DISORDERS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HYPOGLYCEMIC AGENTS; L-LACTATE DEHYDROGENASE; LACTIC ACID; MALE; MEMORY, LONG-TERM; MEMORY, SHORT-TERM; MICE; MICE, TRANSGENIC; MITOCHONDRIA; PEPTIDES; TAU PROTEINS; VENOMS;

ANIMALIA; MUS;

EID: 84879366324     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.139     Document Type: Article

References (56)

1. Messier C, Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res 1996; 75: 1-11.
2. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316-1338.
3. Magarinos AM, McEwen BS. Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci USA 2000; 97: 11056-11061.
4. Grillo CA, Piroli GG, Rosell DR, Hoskin EK, McEwen BS, Reagan LP. Region specific increases in oxidative stress and superoxide dismutase in the hippocampus of diabetic rats subjected to stress. Neuroscience 2003; 121: 133-140.
5. Reagan LP. Glucose, stress, and hippocampal neuronal vulnerability. Int Rev Neurobiol 2002; 51: 289-324.
6. Leedom LJ, Meehan WP, Zeidler A. Avoidance responding in mice with diabetes mellitus. Physiol Behav 1987; 40: 447-451.
7. Alvarez EO, Beauquis J, Revsin Y, Banzan AM, Roig P, De Nicola AF et al. Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes. Behav Brain Res 2009; 198: 224-230.
8. Kim YB, Kotani K, Ciaraldi TP, Henry RR, Kahn BB. Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes 2003; 52: 1935-1942.
9. Cheng B, Mattson MP. IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. J Neurosci 1992; 12: 1558-1566.
10. Dore S, Kar S, Quirion R. Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid-and human amylin-induced toxicity. Proc Natl Acad Sci USA 1997; 94: 4772-4777.
11. Kim SJ, Nian C, McIntosh CH. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure. J Biol Chem 2009; 284: 12896-12904.
12. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-269.
13. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-3438.
14. Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009; 20: 1161-1166.
15. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 377-385.
16. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179.
17. Perry TA, Greig NH. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004; 5: 565-571.
18. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013; 136(Pt 2): 374-384.
19. Chen YR, Huang HB, Chyan CL, Shiao MS, Lin TH, Chen YC. The effect of Abeta conformation on the metal affinity and aggregation mechanism studied by circular dichroism spectroscopy. J Biochem 2006; 139: 733-740.
20. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45: 675-688.
21. Sun X, Beglopoulos V, Mattson MP, Shen J. Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation. Neurodegener Dis 2005; 2: 6-15.
22. Smith IF, Green KN, LaFerla FM. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium 2005; 38: 427-437.
23. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421.
24. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332-1340.
25. Sutherland RJ, McDonald RJ. Hippocampus, amygdala, and memory deficits in rats. Behav Brain Res 1990; 37: 57-79.
26. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19: 1205-1219.
27. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007; 203: 293-301.
28. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 1999; 5: 101-106.
29. Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 7: e32737.
30. Crouch PJ, Cimdins K, Duce JA, Bush AI, Trounce IA. Mitochondria in aging and Alzheimer's disease. Rejuvenation Res 2007; 10: 349-357.
31. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106: 14670-14675.
32. Perry T, Greig NH. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis 2002; 4: 487-496.
33. Isacson R, Nielsen E, Dannaeus K, Bertilsson G, Patrone C, Zachrisson O et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 650: 249-255.
34. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 122: 1339-1353.
35. D'Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 45: 202-207.
36. Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M et al. Effects of longterm treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis 2013; 3: e448.
37. Corona C, Masciopinto F, Silvestri E, Viscovo AD, Lattanzio R, Sorda RL et al. Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death Dis 2010; 1: e91.
38. Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, Piantelli M et al. Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. PLoS One 2011; 6: e17971.
39. Ciavardelli D, Silvestri E, Del Viscovo A, Bomba M, De Gregorio D, Moreno M et al. Alterations of brain and cerebellar proteomes linked to Abeta and tau pathology in a female triple-transgenic murine model of Alzheimer's disease. Cell Death Dis 2010; 1: e90.
40. Perry T, Greig NH. The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 2003; 24: 377-383.
41. Ma TC, Langley B, Ko B, Wei N, Gazaryan IG, Zareen N et al. A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. Neurobiol Dis 2012; 49C: 13-21.
42. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58: 495-505.
43. Strazielle C, Jazi R, Verdier Y, Qian S, Lalonde R. Regional brain metabolism with cytochrome c oxidase histochemistry in a PS1/A246E mouse model of autosomal dominant Alzheimer's disease: correlations with behavior and oxidative stress. Neurochem Int 2009; 55: 806-814.
44. Brown AM, Ransom BR. Astrocyte glycogen and brain energy metabolism. Glia 2007; 55: 1263-1271.
45. Nelson T, Lucignani G, Atlas S, Crane AM, Dienel GA, Sokoloff L. Reexamination of glucose-6-phosphatase activity in the brain in vivo: no evidence for a futile cycle. Science 1985; 229: 60-62.
46. Bouzier-Sore AK, Voisin P, Canioni P, Magistretti PJ, Pellerin L. Lactate is a preferential oxidative energy substrate over glucose for neurons in culture. J Cereb Blood Flow Metab 2003; 23: 1298-1306.
47. Itoh Y, Esaki T, Shimoji K, Cook M, Law MJ, Kaufman E et al. Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proc Natl Acad Sci USA 2003; 100: 4879-4884.
48. Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin JL et al. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci 1998; 20: 291-299.
49. Gordon GR, Choi HB, Rungta RL, Ellis-Davies GC, MacVicar BA. Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 2008; 456: 745-749.
50. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011; 144: 810-823.
51. Newington JT, Pitts A, Chien A, Arseneault R, Schubert D, Cumming RC. Amyloid beta resistance in nerve cell lines is mediated by the Warburg effect. PLoS One 2011; 6: e19191.
52. Newington JT, Rappon T, Albers S, Wong DY, Rylett RJ, Cumming RC. Overexpression of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase A in nerve cells confers resistance to amyloid beta and other toxins by decreasing mitochondrial respiration and reactive oxygen species production. J Biol Chem 2012; 287: 37245-37258.
53. Lanni A, Moreno M, Lombardi A, Goglia F. Calorigenic effect of diiodothyronines in the rat. J Physiol 1996; 494(Pt 3): 831-837.
54. Krieg AF, Rosenblum LJ, Henry JB. Lactate dehydrogenase isoenzymes a comparison of pyruvate-to-lactate and lactate-to-pyruvate assays. Clin Chem 1967; 13: 196-203.
55. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
56. Kanani H, Chrysanthopoulos PK, Klapa MI. Standardizing GC-MS metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 871: 191-201.